Literature DB >> 8070431

Essential hypertension as an endocrine disease.

G H Williams1.   

Abstract

Several lines of evidence strongly suggest that the majority of patients with essential hypertension have an endocrine basis for their elevated blood pressure. Abnormalities in vascular tone, circulating hormone levels, and the responsiveness of target tissues to these hormones all contribute to the pathogenesis of the increased blood pressure. The actual frequency of each of these subsets of patients is unknown, but it is likely to be substantial. Intriguingly, most of these abnormalities are not associated with hormonal overproduction per se but, rather, a change in the response of target tissues to specific hormones, with compensatory mechanisms actually responsible for the increased blood pressure. There is evidence that each of these endocrine abnormalities may be inherited, so there is a high likelihood that a genetic marker can be found to identify each subgroup. Already there is the intriguing possibility that if subgroups of patients can be identified easily, specific therapy will be possible.

Entities:  

Mesh:

Year:  1994        PMID: 8070431

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  3 in total

1.  Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors.

Authors:  Erik L Meredith; Gary Ksander; Lauren G Monovich; Julien P N Papillon; Qian Liu; Karl Miranda; Patrick Morris; Chang Rao; Robin Burgis; Michael Capparelli; Qi-Ying Hu; Alok Singh; Dean F Rigel; Arco Y Jeng; Michael Beil; Fumin Fu; Chii-Whei Hu; Daniel LaSala
Journal:  ACS Med Chem Lett       Date:  2013-10-17       Impact factor: 4.345

2.  Dissociation of hyperglycemia from altered vascular contraction and relaxation mechanisms in caveolin-1 null mice.

Authors:  Luminita H Pojoga; Tham M Yao; Lauren A Opsasnick; Amanda E Garza; Ossama M Reslan; Gail K Adler; Gordon H Williams; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2013-11-26       Impact factor: 4.030

3.  Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.

Authors:  Joël Ménard; Dean F Rigel; Catherine Watson; Arco Y Jeng; Fumin Fu; Michael Beil; Jing Liu; Wei Chen; Chii-Whei Hu; Jennifer Leung-Chu; Daniel LaSala; Guiqing Liang; Sam Rebello; Yiming Zhang; William P Dole
Journal:  J Transl Med       Date:  2014-12-10       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.